Blog

Howard McLeod: Preemptive DPYD Testing Program for patients planned for a systemic Fluoropyrimidine

Photo taken from Howard McLeod/LinkedIn

May 1, 2024, 04:54

Howard McLeod: Preemptive DPYD Testing Program for patients planned for a systemic Fluoropyrimidine

Howard McLeod, Central Director, Founder and Advisor at Precision Medicine, shared on LinkedIn:

“The USA cancer community might be late to adopt Dihydropyrimidine dehydrogenase (DPYD) testing to avoid severe/fatal toxicity from commonly used chemotherapy, but the tide has finally changed. The recent Food and Drug Administration (FDA) package insert change is followed by very successful implementation at Dana-Farber Cancer Institute. With data from community centers, such as Atrium Health and St. Elizabeth Healthcare, there are no more excuses for rest of the field.”

Additional information
Source: Howard McLeod/LinkedIn

ASCO Atrium Health cancer Childhood Cancer Dana-Farber Cancer Institute dihydropyrimidine dehydrogenase DPYD testing FDA fluoropyrimidine Howard McLeod OncoDaily Oncology St. Elizabeth Healthcare

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer